| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 1969 | 2014 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1530 | 2015 |
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ... Annals of Oncology 28 (7), 1631-1639, 2017 | 715 | 2017 |
| Sequence variants at the TERT-CLPTM1L locus associate with many cancer types T Rafnar, P Sulem, SN Stacey, F Geller, J Gudmundsson, A Sigurdsson, ... Nature genetics 41 (2), 221-227, 2009 | 703 | 2009 |
| Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling A Mandic, J Hansson, S Linder, MC Shoshan Journal of Biological Chemistry 278 (11), 9100-9106, 2003 | 658 | 2003 |
| Geographical variation in the penetrance of CDKN2A mutations for melanoma DT Bishop, F Demenais, AM Goldstein, W Bergman, JN Bishop, ... Journal of the National Cancer Institute 94 (12), 894-903, 2002 | 621 | 2002 |
| A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma O Hamid, H Schmidt, A Nissan, L Ridolfi, S Aamdal, J Hansson, M Guida, ... Journal of translational medicine 9, 1-16, 2011 | 611 | 2011 |
| FBXW7/hCDC4 is a general tumor suppressor in human cancer S Akhoondi, D Sun, N von der Lehr, S Apostolidou, K Klotz, A Maljukova, ... Cancer research 67 (19), 9006-9012, 2007 | 574 | 2007 |
| Genome-wide association study identifies three loci associated with melanoma risk DT Bishop, F Demenais, MM Iles, M Harland, JC Taylor, E Corda, ... Nature genetics 41 (8), 920-925, 2009 | 541 | 2009 |
| NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression K Omholt, A Platz, L Kanter, U Ringborg, J Hansson Clinical cancer research 9 (17), 6483-6488, 2003 | 528 | 2003 |
| Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents AM Goldstein, M Chan, M Harland, NK Hayward, F Demenais, DT Bishop, ... Journal of medical genetics 44 (2), 99-106, 2007 | 524 | 2007 |
| High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL AM Goldstein, M Chan, M Harland, EM Gillanders, NK Hayward, MF Avril, ... Cancer research 66 (20), 9818-9828, 2006 | 505 | 2006 |
| Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign I Poschke, D Mougiakakos, J Hansson, GV Masucci, R Kiessling Cancer research 70 (11), 4335-4345, 2010 | 485 | 2010 |
| A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women MB Veierød, E Weiderpass, M Thörn, J Hansson, E Lund, B Armstrong, ... Journal of the National Cancer Institute 95 (20), 1530-1538, 2003 | 466 | 2003 |
| Hydrogen peroxide secreted by tumor‐derived macrophages down‐modulates signal‐transducing zeta molecules and inhibits tumor‐specific T cell‐and natural killer cell‐mediated … K Kono, F Salazar‐Onfray, M Petersson, J Hansson, G Masucci, ... European journal of immunology 26 (6), 1308-1313, 1996 | 424 | 1996 |
| Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2 … EA Rozeman, AM Menzies, ACJ van Akkooi, C Adhikari, C Bierman, ... The Lancet Oncology 20 (7), 948-960, 2019 | 421 | 2019 |
| Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. M Matsuda, F Salazar, M Petersson, G Masucci, J Hansson, P Pisa, ... The Journal of experimental medicine 180 (6), 2371-2376, 1994 | 417 | 1994 |
| ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma DF Gudbjartsson, P Sulem, SN Stacey, AM Goldstein, T Rafnar, ... Nature genetics 40 (7), 886-891, 2008 | 410 | 2008 |
| Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas KSM Smalley, M Lioni, MD Palma, M Xiao, B Desai, S Egyhazi, J Hansson, ... Molecular cancer therapeutics 7 (9), 2876-2883, 2008 | 383 | 2008 |
| Skin cancer identification using multifrequency electrical impedance-a potential screening tool P Aberg, I Nicander, J Hansson, P Geladi, U Holmgren, S Ollmar IEEE transactions on biomedical engineering 51 (12), 2097-2102, 2004 | 373 | 2004 |
Paolo A. AsciertoIstituto Nazionale Tumori Fondazione "G. Pascale", Napoli, ItalyVerified email at istitutotumori.na.it
